Literature DB >> 29136505

Inhibition of TRF1 Telomere Protein Impairs Tumor Initiation and Progression in Glioblastoma Mouse Models and Patient-Derived Xenografts.

Leire Bejarano1, Alberto J Schuhmacher2, Marinela Méndez1, Diego Megías3, Carmen Blanco-Aparicio4, Sonia Martínez4, Joaquín Pastor4, Massimo Squatrito2, Maria A Blasco5.   

Abstract

Glioblastoma multiforme (GBM) is a deadly and common brain tumor. Poor prognosis is linked to high proliferation and cell heterogeneity, including glioma stem cells (GSCs). Telomere genes are frequently mutated. The telomere binding protein TRF1 is essential for telomere protection, and for adult and pluripotent stem cells. Here, we find TRF1 upregulation in mouse and human GBM. Brain-specific Trf1 genetic deletion in GBM mouse models inhibited GBM initiation and progression, increasing survival. Trf1 deletion increased telomeric DNA damage and reduced proliferation and stemness. TRF1 chemical inhibitors mimicked these effects in human GBM cells and also blocked tumor sphere formation and tumor growth in xenografts from patient-derived primary GSCs. Thus, targeting telomeres throughout TRF1 inhibition is an effective therapeutic strategy for GBM.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  TRF1; glioblastoma; glioma stem cells; shelterin; stemness; telomeres; therapy

Mesh:

Substances:

Year:  2017        PMID: 29136505     DOI: 10.1016/j.ccell.2017.10.006

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  21 in total

1.  Cancer: Targeting telomeres.

Authors:  Sarah Crunkhorn
Journal:  Nat Rev Drug Discov       Date:  2017-12-28       Impact factor: 84.694

2.  Cancer cells induce immune escape via glycocalyx changes controlled by the telomeric protein TRF2.

Authors:  Julien Cherfils-Vicini; Charlene Iltis; Ludovic Cervera; Sabrina Pisano; Olivier Croce; Nori Sadouni; Balázs Győrffy; Romy Collet; Valérie M Renault; Martin Rey-Millet; Carlo Leonetti; Pasquale Zizza; Fabrice Allain; Francois Ghiringhelli; Nicolas Soubeiran; Marina Shkreli; Eric Vivier; Annamaria Biroccio; Eric Gilson
Journal:  EMBO J       Date:  2019-04-18       Impact factor: 11.598

Review 3.  Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies.

Authors:  Jixuan Gao; Hilda A Pickett
Journal:  Nat Rev Cancer       Date:  2022-07-05       Impact factor: 69.800

4.  miR-490 suppresses telomere maintenance program and associated hallmarks in glioblastoma.

Authors:  Omkar Suhas Vinchure; Kurt Whittemore; Deependra Kushwah; Maria A Blasco; Ritu Kulshreshtha
Journal:  Cell Mol Life Sci       Date:  2020-09-24       Impact factor: 9.261

Review 5.  Non-canonical roles of canonical telomere binding proteins in cancers.

Authors:  Semih Can Akincilar; Claire Hian Tzer Chan; Qin Feng Ng; Kerem Fidan; Vinay Tergaonkar
Journal:  Cell Mol Life Sci       Date:  2021-02-18       Impact factor: 9.261

Review 6.  Telomeres: Implications for Cancer Development.

Authors:  Aina Bernal; Laura Tusell
Journal:  Int J Mol Sci       Date:  2018-01-19       Impact factor: 5.923

Review 7.  Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer.

Authors:  Ryan C Gimple; Shruti Bhargava; Deobrat Dixit; Jeremy N Rich
Journal:  Genes Dev       Date:  2019-06-01       Impact factor: 11.361

8.  HDACs control RUNX2 expression in cancer cells through redundant and cell context-dependent mechanisms.

Authors:  Gloria Manzotti; Federica Torricelli; Benedetta Donati; Valentina Sancisi; Mila Gugnoni; Alessia Ciarrocchi
Journal:  J Exp Clin Cancer Res       Date:  2019-08-08

9.  Telomere-related Markers for Cancer.

Authors:  Xiaotian Yuan; Mingkai Dai; Dawei Xu
Journal:  Curr Top Med Chem       Date:  2020       Impact factor: 3.295

Review 10.  Personalized regulation of glioblastoma cancer stem cells based on biomedical technologies: From theory to experiment (Review).

Authors:  Igor Bryukhovetskiy; Arina Ponomarenko; Irina Lyakhova; Sergey Zaitsev; Yulia Zayats; Maria Korneyko; Marina Eliseikina; Polina Mischenko; Valerie Shevchenko; Hari Shanker Sharma; Aruna Sharma; Yuri Khotimchenko
Journal:  Int J Mol Med       Date:  2018-05-10       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.